Members of blues-rock powerhouse Fleetwood Mac on Tuesday announced a new album that will bring together all of the band’s classic lineup—except Stevie Nicks.
Guitarist Lindsey Buckingham said the album would be the first by a duo of him and keyboardist Christine McVie, who rejoined Fleetwood Mac for a 2014-15 global tour after staying out of the spotlight for years.
Entitled simply “Lindsey Buckingham/Christine McVie,” the 10-track album will come out on June 9 followed by a US tour. The duo will release a first single, “In My World,” on Friday.
The duo in a statement said that the two started working on new material when McVie joined rehearsals for the tour and “their natural creative chemistry was reignited.”
Recording the album at the Los Angeles studio where Fleetwood Mac made its 1979 album “Tusk,” the pair was joined by two band mates—drummer Mick Fleetwood and bassist John McVie.
Notably absent from the recording sessions was Stevie Nicks, who has gone on to become the most identifiable member of Fleetwood Mac with a successful solo career led by her unique sandy voice.
Buckingham, in a 2014 interview with Billboard magazine, had said that Nicks was busy with other commitments when the others headed to the studio.
The part-British, part-US band was notorious for internal tensions which played out in the music. Nicks was romantically involved at times with Buckingham and Fleetwood, while Christine McVie was formerly married to John McVie.
Fleetwood Mac has not released a studio album since 2003’s “Say You Will,” on which Christine McVie was absent, but the reunited lineup with Nicks has become a major draw on the live circuit.
Fleetwood Mac and The Eagles will headline a new festival called The Classic in Los Angeles and New York in July.
Method to stop cancer from mutating and spreading developed by Australian researchers
Australian scientists have made a breakthrough in preventing cancer from mutating in the body.
The team from Melbourne’s Olivia Newton-John (ONJ) Cancer Wellness and Research Centre have been able to interrupt the body’s wound-healing process and lock cancer cells into a “harmless” state before they can mutate and spread.
The process has proved successful in treating colon and stomach cancer and lead researcher Matthias Ernst believes it could be applied to other cancers.
Instead of targeting cancer cells themselves, the ONJ breakthrough
interrupts a white blood cell process called macrophages which has been known to fight cancer.
However, if the macrophage cells are exposed to a wound then the HCK
protein signals the cells to take on a nursing role, prompting extra skin cells to grow and cover the wound.
The research team discovered that cancer cells can hijack the healing properties and use white blood cells to fuel their own growth rather than skin cells.
By blocking the HCK protein and preventing the macrophage cells from
changing to a nursing role to begin with, Ernst’s team has been able to suppress the growth of established tumours.
“We have identified a way you can therapeutically target the non-mutated cells in a cancer. The advantage of that is because they are non-mutated they are less likely to develop resistance,” Ernst told News Limited on Wednesday.
“We know very well how to inhibit these molecules, and therefore it is
very foreseeable on how you would develop a drug that can inhibit the
activity of the HCK and therefore lock the macrophage into garbage collector state and rather than allowing them to become nurses.”
Ernst said his team was currently working to develop a drug capable of safely freezing the process with human clinical trials on the horizon, reports Xinhua, Sydney.
